Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Public ClinicalTrials.gov record NCT00137436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
Study identification
- NCT ID
- NCT00137436
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2005
- Primary completion
- Apr 30, 2008
- Completion
- Feb 28, 2010
- Last update posted
- Aug 28, 2011
2005 – 2010
United States locations
- U.S. sites
- 24
- U.S. states
- 8
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Harvey | Illinois | 60426 | — |
| Pfizer Investigational Site | Tinley Park | Illinois | 60477 | — |
| Pfizer Investigational Site | Hobart | Indiana | 46342 | — |
| Pfizer Investigational Site | Munster | Indiana | 46321 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239-3098 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239 | — |
| Pfizer Investigational Site | Myrtle Beach | South Carolina | 29572 | — |
| Pfizer Investigational Site | Clarksville | Tennessee | 37043 | — |
| Pfizer Investigational Site | Franklin | Tennessee | 37067 | — |
| Pfizer Investigational Site | Gallarin | Tennessee | 37066 | — |
| Pfizer Investigational Site | Hermitage | Tennessee | 37076 | — |
| Pfizer Investigational Site | Lebanon | Tennessee | 37087 | — |
| Pfizer Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37207 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37211 | — |
| Pfizer Investigational Site | Smithville | Tennessee | 37166 | — |
| Pfizer Investigational Site | Smyrna | Tennessee | 37167 | — |
| Pfizer Investigational Site | Tullahoma | Tennessee | 37388 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00137436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2011 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00137436 live on ClinicalTrials.gov.